Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Well Worth Watching

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss making companies can act like a sponge for capital - so investors should be cautious that they're not throwing good money after bad.

If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Sun Pharmaceutical Industries (NSE:SUNPHARMA). Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Sun Pharmaceutical Industries with the means to add long-term value to shareholders.

Our free stock report includes 1 warning sign investors should be aware of before investing in Sun Pharmaceutical Industries. Read for free now.

Sun Pharmaceutical Industries' Earnings Per Share Are Growing

Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. That means EPS growth is considered a real positive by most successful long-term investors. It certainly is nice to see that Sun Pharmaceutical Industries has managed to grow EPS by 21% per year over three years. As a general rule, we'd say that if a company can keep up that sort of growth, shareholders will be beaming.

One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. Sun Pharmaceutical Industries shareholders can take confidence from the fact that EBIT margins are up from 22% to 24%, and revenue is growing. That's great to see, on both counts.

You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.

See our latest analysis for Sun Pharmaceutical Industries

In investing, as in life, the future matters more than the past. So why not check out this free interactive visualization of Sun Pharmaceutical Industries' forecast profits?

Are Sun Pharmaceutical Industries Insiders Aligned With All Shareholders?

We would not expect to see insiders owning a large percentage of a ₹4.1t company like Sun Pharmaceutical Industries. But we are reassured by the fact they have invested in the company. Indeed, they have a considerable amount of wealth invested in it, currently valued at ₹492b. That equates to 12% of the company, making insiders powerful and aligned with other shareholders. So there is opportunity here to invest in a company whose management have tangible incentives to deliver.

It means a lot to see insiders invested in the business, but shareholders may be wondering if remuneration policies are in their best interest. Well, based on the CEO pay, you'd argue that they are indeed. For companies with market capitalisations over ₹682b, like Sun Pharmaceutical Industries, the median CEO pay is around ₹93m.

Sun Pharmaceutical Industries' CEO took home a total compensation package worth ₹61m in the year leading up to March 2024. That seems pretty reasonable, especially given it's below the median for similar sized companies. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. It can also be a sign of a culture of integrity, in a broader sense.

Should You Add Sun Pharmaceutical Industries To Your Watchlist?

For growth investors, Sun Pharmaceutical Industries' raw rate of earnings growth is a beacon in the night. If you still have your doubts, remember too that company insiders have a considerable investment aligning themselves with the shareholders and CEO pay is quite modest compared to similarly sized companiess. This may only be a fast rundown, but the key takeaway is that Sun Pharmaceutical Industries is worth keeping an eye on. Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Sun Pharmaceutical Industries that you should be aware of.

Although Sun Pharmaceutical Industries certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of Indian companies that not only boast of strong growth but have strong insider backing.

Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.